Table 2.
Case | Bone metastasis | Primary | Time from | Time from | |||||
---|---|---|---|---|---|---|---|---|---|
PIK3CA
status |
ER status | PgR status | HER2 status | ER status | PgR status | HER2 status | cancer diagnosis (years) | metastatic cancer diagnosis (years) | |
2 | E545K | pos. | pos. | normal | pos. | pos. | normal | 11 | 11 |
3 | WT | pos. | neg. | normal | pos. | neg. | normal | 11 | 1 |
4 | H1047R | pos. | neg. | normal | pos. | pos. | normal | 14 | 2 |
11 | WT | pos. | pos. | normal | pos. | pos. | normal | 23 | 21 |
12 | H1047R hom. | pos.* | neg.* | amplified* | pos. | neg. | amplified | <1 | <1 |
13 | WT | pos. | neg. | normal | pos. | pos. | normal | <1 | <1 |
Estrogen (ER) and progesterone (PgR) statuses are shown as positive (pos.) or negative (neg.). Time from cancer diagnosis and metastatic cancer diagnosis is the time between diagnosis and the biopsy taken for this study. *determined from CT-guided bone biopsy; other metastasis receptor and HER2 data are determined from trephine biopsies.